Antiemetic effect of palonosetron in advanced colorectal cancer patients receiving mFOLFOX6 and folfiri: A retrospective survey

Japanese Journal of Cancer and Chemotherapy

Volumn 39, Issue 8, 2012, Pages 1215-1219

  Sato, Yumiko ^a,e   Hayakawa, Yuji ^b   Tatematsu, Michiko ^c,e   Muro, Kei ^d   Noma, Hidekazu ^a   Okamoto, Hirokazu ^e  

^a Nagoya City University West Medical Center   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^c Dept of Pharmacy ^*  (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e MEIJO UNIVERSITY   (Japan)

Author keywords

Chemotherapy induced nausea and vomiting (CINV); FOLFIRI; mFOLFOX6; Palonosetron

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GRANISETRON; IRINOTECAN; OXALIPLATIN; PALONOSETRON;

ADVANCED CANCER; ANTIEMETIC ACTIVITY; APPETITE DISORDER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COLORECTAL CANCER; DRUG EFFICACY; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY;

EID: 84867612858     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Kris MG, Hesketh PJ, Somerfield MR, et al: American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24(18): 2932-2947, 2006.
2. National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology: Guidelines for Supportive Care Antiemesis, V1.2012.
3. Roila F, Herrstedt J, Aapro M, et al: Guideline update for MASCC and ESMO in the prevention of chemotherapy and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5): v232-v243, 2010.
4. Grunberg SM and Koeller JM: Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis. Expert Opin Pharmacother 4(12): 2297-2303, 2003.
5. Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22(4): 229-237, 2004.
6. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22(1): 23-30, 2004.
7. Fuse N, Doi T, Ohtsu A, et al: Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer. Int J Clin Oncol 13(2): 144-149, 2008.
8. Sobrero A, Ackland S, Clarke S, et al: Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 77(2): 113-119, 2009.
9. Aapro MS, Grunberg SM, Manikhas GM, et al: A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17(9): 1441-1449, 2006.
10. Saito M, Aogi K, Sekine I, et al: Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10(2): 115-124, 2009.
11. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al: Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist. Cancer 98(11): 2473-2482, 2003.
12. Gralla R, Lichinitser M, Van der Vegt S, et al: Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14(10): 1570-1577, 2003.
13. Hesketh PJ: Chemotherapy-induced nausea and vomiting. N Engl J Med 358(23): 2482-2494, 2008.
14. Hesketh PJ, Aapro M, Street JC, et al: Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer 18(9): 1171-1177, 2010.